Checkpoint therapies before surgery? MD Anderson team reports encouraging efficacy but worries about toxicity
Days after the Nobel committee honored immunotherapy in this year’s medicine prize, MD Anderson, where Nobel winner Jim Allison currently works, has some new human data — and lessons — about a novel way to use checkpoint inhibitors.
While checkpoint drugs like Opdivo (nivolumab) and Yervoy (ipilimumab) are often given to melanoma patients after surgery or when their cancer is unresectable, researchers wanted to know if administering them before surgery could be an effective approach.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.